Federal health officials on Wednesday advised the more than 150 million Americans who've gotten two doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines that they should get a third shot starting Sept. 20.
But what about the 14 million who opted for the one-and-done Johnson & Johnson vaccine? "We anticipate vaccine boosters will likely be needed" for them, too, Surgeon General Vivek Murthy said at a White House briefing. "We expect more data on J&J in the coming weeks. With those data in hand, we will keep the public informed of a timely plan for J&J booster shots."
The Biden administration is pushing a booster shot because the mRNA vaccines, Pfizer and Moderna, appear to be losing some efficacy against the much more transmissible Delta variant. There's less data for the Johnson & Johnson shot's longevity, though Johnson & Johnson told The New York Times it will "will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine," probably "in the coming weeks."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"If you're doing data-driven decisions and you don't have the data, what can you do?" asked John Moore, a virologist at Weill Cornell Medicine. He told the Times he "would be very, very surprised" if the U.S. didn't approve a second J&J shot "in the reasonably near future," adding, "The federal government is well aware of the J.&J. situation. ... It's not being overlooked."
Dr. Dan Barouch, a virologist at Boston's Beth Israel Deaconess Medical Center, said new real-world data from health workers in South Africa has "very clear results showing that the single-shot J&J vaccine provided substantial protection against the Delta variant." Barouch and Moore said they expect that when the booster shot is approved, it will be for a second J&J dose, not Pfizer or Moderna.
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
